Lanreotide vs Pasireotide
A depot somatostatin analog, similar in action to octreotide. A broader-spectrum somatostatin analog hitting more receptor subtypes. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Lanreotide | Pasireotide | |
|---|---|---|
| Also known as | Somatuline | Signifor |
| Type | Analog | Analog |
| Evidence | Established | Established |
| Family | Growth & repair | Growth & repair |
| Class | Somatostatin analog (cyclic octapeptide) | Somatostatin analog (cyclic hexapeptide) |
| Receptor | Somatostatin receptors (SSTR2 and SSTR5 preferential) | Somatostatin receptors (SSTR1, 2, 3, and 5) |
| Molecular weight | ~1,096.3 Da | ~1,047.2 Da |
| Half-life | depot-dominant (autogel acts over weeks) | |
| Based on | Somatostatin | Somatostatin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Lanreotide and Pasireotide?
- Lanreotide is an engineered analog based on Somatostatin; Pasireotide is an engineered analog based on Somatostatin. Lanreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential); Pasireotide signals at Somatostatin receptors (SSTR1, 2, 3, and 5).
- How do the half-lives of Lanreotide and Pasireotide compare?
- The reported circulating half-life of Lanreotide is depot-dominant (autogel acts over weeks); Pasireotide is ~12 h. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Lanreotide the same as Somatuline?
- Somatuline is a brand name of Lanreotide. This comparison describes the molecules, not branded products.
Prefer the other order? Pasireotide vs Lanreotide. Or open the interactive comparison tool to add more molecules.